Nuveen Asset Management, LLC - IOVANCE BIOTHERAPEUTICS INC ownership

IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 171 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.14 and the average weighting 0.7%.

Quarter-by-quarter ownership
Nuveen Asset Management, LLC ownership history of IOVANCE BIOTHERAPEUTICS INC
ValueSharesWeighting
Q3 2023$7,295,821
-53.5%
1,603,477
-28.1%
0.00%
-40.0%
Q2 2023$15,694,138
+119065.8%
2,229,281
+3.4%
0.01%0.0%
Q1 2023$13,170
+53.0%
2,155,542
+60.0%
0.01%
+66.7%
Q4 2022$8,607
-99.9%
1,346,919
-22.5%
0.00%
-57.1%
Q3 2022$16,654,000
-16.1%
1,738,385
-3.3%
0.01%
-12.5%
Q2 2022$19,855,000
+184.2%
1,798,549
+286.1%
0.01%
+300.0%
Q1 2022$6,987,000
-46.0%
465,777
-31.2%
0.00%
-50.0%
Q4 2021$12,928,000
-14.8%
677,207
+10.1%
0.00%
-20.0%
Q3 2021$15,173,000
-6.8%
615,278
-1.6%
0.01%0.0%
Q2 2021$16,274,000
-16.4%
625,457
+1.7%
0.01%
-16.7%
Q1 2021$19,473,000
-36.5%
615,058
-7.0%
0.01%
-40.0%
Q4 2020$30,687,000
+62.7%
661,362
+15.4%
0.01%
+42.9%
Q3 2020$18,864,000
+23.9%
572,999
+3.3%
0.01%
+16.7%
Q2 2020$15,225,000
-35.7%
554,672
-29.8%
0.01%
-50.0%
Q1 2020$23,664,000
+32.1%
790,503
+22.1%
0.01%
+71.4%
Q4 2019$17,914,000
+30.7%
647,190
-14.0%
0.01%
+16.7%
Q3 2019$13,704,000
-21.9%
752,939
+5.2%
0.01%
-14.3%
Q2 2019$17,554,000
+5171.5%
715,908
+1946.3%
0.01%
+250.0%
Q1 2019$333,00034,9860.00%
Other shareholders
IOVANCE BIOTHERAPEUTICS INC shareholders Q2 2019
NameSharesValueWeighting ↓
MHR Fund Management 11,997,103$84,459,60511.88%
MPM BioImpact LLC 2,950,118$20,768,8314.18%
Perceptive Advisors 14,036,410$98,816,3262.86%
Velan Capital Investment Management LP 240,000$1,689,6001.57%
Parametrica Management Ltd 96,500$679,3601.31%
Boxer Capital, LLC 3,705,133$26,0841.21%
Soleus Capital Management, L.P. 1,239,777$8,728,0300.97%
Opaleye Management Inc. 421,000$2,963,8400.71%
683 Capital Management, LLC 1,400,000$9,856,0000.71%
RICE HALL JAMES & ASSOCIATES, LLC 1,758,759$12,381,6650.70%
View complete list of IOVANCE BIOTHERAPEUTICS INC shareholders